Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
853.35B
Market cap853.35B
Price-Earnings ratio
40.08
Price-Earnings ratio40.08
Dividend yield
0.68%
Dividend yield0.68%
Average volume
2.56M
Average volume2.56M
High today
$923.05
High today$923.05
Low today
$881.11
Low today$881.11
Open price
$910.18
Open price$910.18
Volume
4.05M
Volume4.05M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 853.35B, Eli Lilly(LLY) trades at $909.29. The stock has a price-to-earnings ratio of 40.08 and currently yields dividends of 67.7%.

During the trading session on 2026-04-21, Eli Lilly(LLY) shares reached a daily high of $923.05 and a low of $881.11. At a current price of $909.29, the stock is +3.2% higher than the low and still -1.5% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 4.05M, versus its average volume of 2.56M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

TipRanks 4h
UBS Pounds the Table on Eli Lilly Stock After Kelonia Therapeutics Deal

Analysts at Swiss bank UBS Group (UBS) are urging investors to buy Eli Lilly (LLY) stock after the pharma giant announced it is paying $7 billion to acquire can...

TipRanks 5h
Lilly, Novo slip after CVS opts out of Medicare obesity drug model

Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) are under pressure on Tuesday after CVS Health (CVS) announced the company’s decision regarding Medicare obesit...

Investor's Business Daily 6h
Amazon Stock: Anthropic And OpenAI Deals Highlight 'Growing Confidence' In Custom AI Chips

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. 3:58 AM ET Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics tumbled Tuesday after Am...

Amazon Stock: Anthropic And OpenAI Deals Highlight 'Growing Confidence' In Custom AI Chips

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

Nasdaq 6h
Why Did Eli Lilly Stock Drop Today?

Key Points Eli Lilly is spending some of its GLP-1 money to buy up CAR-T gene therapy researchers. UBS analyst Michael Yee thinks that's smart strategy. 10 s...

Why Did Eli Lilly Stock Drop Today?
Nasdaq 10h
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Key Points Novo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market. The two companies, however, can’t fend off creativ...

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Simply Wall St 22h
Eli Lilly’s US$7b Kelonia Deal Expands Oncology And Valuation Opportunity

Eli Lilly (NYSE:LLY) has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7b. The deal expands Eli Lilly's presence in in vivo CAR T ce...

Eli Lilly’s US$7b Kelonia Deal Expands Oncology And Valuation Opportunity
Cheddar 1d
Lilly’s $7 Billion Bet on Next-Gen Cancer Therapy

Eli Lilly is making a bold move, agreeing to acquire Kelonia Therapeutics in a deal worth up to $7 billion, with billions tied to future milestones and a plans....

Lilly’s $7 Billion Bet on Next-Gen Cancer Therapy
Investor's Business Daily 1d
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others

Technology Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others Licensing Eli Lilly (LLY) said Monday it will spend up to $7 billion to buy priva...

Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
TipRanks 1d
M&A News: Eli Lilly Announces Blockbuster $7 Billion Acquisition of Kelonia Therapeutics

Eli Lilly (LLY) is acquiring Boston-based Kelonia Therapeutics in a blockbuster $7 billion deal. Unlock hedge fund-level data and powerful investing tools for...

TipRanks 1d
Eli Lilly to acquire Kelonia Therapeutics; Kelonia to receive up to $7B in cash

Eli Lilly (LLY) and Kelonia Therapeutics announced a definitive agreement for Lilly to acquire Kelonia. Under the terms of the agreement, Lilly will acquire Kel...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.